Aurora Cannabis Logo
CA05156X8843
A2P4EC
21P1.F

Aurora Cannabis

Prognose

Køb
  0
Behold
  5
Sælg
  2

Diskussioner i communityet

  • Holding bleibt erhalten trotz löschbestätigung

    PN Parqet Nutzer V i Schnack

    0 4
  • Probleme mit meinem Depot...

    MaxPower MaxPower V i Schnack

    0 23
  • Chartausreißer

    W Wolfgang II i Schnack

    0 12

  • Aurora Cannabis records 11% revenue growth in 2026 and debt-free balance sheet, stock falls

    Aurora Cannabis reported net revenue of CAD 321 million for fiscal 2026 (+11%) and adjusted EBITDA of CAD 54 million (+32%). Growth was driven by international expansion and a focus on higher-margin medical cannabis; international markets accounted for 55% of revenue. The company is debt-free and holds CAD 165 million in cash, and it forecasts Q1 FY2027 EPS of -0.08 USD and revenue of USD 54.94 million. The stock fell 2.96% after the results were released. » Mere på de.investing.com


  • Aurora Cannabis expects decline in quarterly revenue and moderate loss per share

    Aurora Cannabis will release results for the quarter ended 31/03/2026 on 11/06/2026. Five analysts expect an average loss of -0.058 CAD per share (prior year: -0.350 CAD) and six analysts forecast revenue of 75.7 million CAD, about 16.4% below last year’s 90.5 million CAD. For the past fiscal year, five analysts estimate an average loss of -1.197 CAD per share and six analysts see annual revenue at 358.4 million CAD (prior year: 343.3 million CAD). » Mere på finanzen.net


  • Aurora Cannabis expands medical portfolio in Canada, Europe and Australia

    Aurora Cannabis will launch new medical cannabis products by June in Canada, Germany, Poland and Australia, including dried flower, pre-rolls and lozenges. In Germany the company will offer San Raf Pink OG Kush (25–27% THC) and Daily Special Lemon Sorbet (21% THC); Poland and Australia will also receive high‑potency strains and multi‑stage lozenge formulations. The products are manufactured in GMP‑certified facilities in Canada and Germany and are part of the company’s international “Medical‑First” strategy. Aurora has a market capitalization of about USD 207.74 million and recorded a 25% share price decline in the past year, while InvestingPro currently rates the stock as undervalued. » Mere på de.investing.com


  • Aurora Cannabis buys Safari Flower for $26.5 million to bolster EU‑GMP capacity

    Aurora Cannabis is acquiring the Safari Flower Company for $26.5 million, to be paid with $15 million in cash, 2,417,180 common shares and a conditional $2 million earn‑out. Safari operates a 59,000‑square‑foot EU‑GMP‑certified indoor facility in Ontario, whose capacity Aurora plans to use for exports to Germany, Australia, Poland and the UK. The acquisition represents about 13% of Aurora’s market capitalization and is expected to contribute positively to adjusted EBITDA from fiscal 2027, with further effects anticipated from 2028. » Mere på de.investing.com


  • Aurora Cannabis: revenue rises, but net loss in third quarter

    Aurora Cannabis reported a net loss from continuing operations of CAD 1.7 million in the third quarter of fiscal 2026, compared with a net profit of CAD 28.1 million a year earlier. Revenue rose to CAD 94.191 million (prior year CAD 88.2 million) and exceeded analysts’ expectations of CAD 92.4 million. Adjusted net income remained virtually unchanged at CAD 7.2 million; the global medical cannabis business posted record quarterly net revenue of USD 76.2 million, adjusted EBITDA of USD 18.5 million and free cash flow of USD 15.5 million. The stock reacted with declines, dropping as much as about 6.2% to USD 3.81. » Mere på finanzen.net

Virksomhedstal

I det seneste år havde Aurora Cannabis en omsætning på 270,28 mio. € og et nettoresultat på -69,33 mio. €

(EUR) 2024
YoY
Omsætning 270,28 mio. 15,86 %
Bruttofortjeneste 131,46 mio. 304,26 %
Nettoresultat -69,33 mio. 73,87 %
EBITDA -12,34 mio. 94,14 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
19,64 mio. €
Antal aktier
54,54 mio.
Højeste/laveste i 52 uger
1,08 € - 0,35 €
Udbytte Nej
Beta
2,86
P/E (PE Ratio)
-4,44
PEG (PEG Ratio)
0,03
K/I (PB Ratio)
0,75
P/S (PS Ratio)
1,37

Virksomhedsprofil

Aurora Cannabis Inc. producerer, distribuerer og sælger cannabis og cannabisafledte produkter i Canada og internationalt. Selskabet beskæftiger sig også med faciliteters engineering og design, cannabisavl, forskning, produktion, derivater, produktudvikling, engros- og detaildistributionsaktiviteter. Virksomheden producerer forskellige sorter af tørret cannabis, cannabisolie og kapsler samt topiske sæt til medicinske patienter. Den sælger også vaporizere, forbrugsvarer til vaporizere og urtekværne til brug med CanniMed urtebaserede cannabisprodukter, samt knusere og låsbare beholdere til vaporizere. Derudover beskæftiger selskabet sig med udvikling af medicinske cannabisprodukter på forskellige udviklingsstadier, herunder orale, topiske, spiselige og inhalerbare produkter; og driften af CanvasRX, et netværk af rådgivnings- og oplysningscentre for cannabis. Desuden tilbyder det patientrådgivningsydelser, design- og byggeydelser samt analytiske produkttestydelser for cannabis. Selskabets brandportefølje omfatter Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock og WMMC. Aurora Cannabis Inc. har hovedkontor i Edmonton, Canada.

Navn
Aurora Cannabis
CEO
Miguel Martin
Hjemsted Edmonton, ab
Canada
Websted
Sektor
Sundhed
Branche
Lægemidler
Børsnotering
15.07.2014
Medarbejdere 1.130

Tickersymboler

Børs Symbol
XETRA
21P1.F
🍪

Parqet  bruger cookies. Læs mere